Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Proc Natl Acad Sci U S A ; 119(4)2022 01 25.
Artículo en Inglés | MEDLINE | ID: mdl-35058360

RESUMEN

Topoisomerases nick and reseal DNA to relieve torsional stress associated with transcription and replication and to resolve structures such as knots and catenanes. Stabilization of the yeast Top2 cleavage intermediates is mutagenic in yeast, but whether this extends to higher eukaryotes is less clear. Chemotherapeutic topoisomerase poisons also elevate cleavage, resulting in mutagenesis. Here, we describe p.K743N mutations in human topoisomerase hTOP2α and link them to a previously undescribed mutator phenotype in cancer. Overexpression of the orthologous mutant protein in yeast generated a characteristic pattern of 2- to 4-base pair (bp) duplications resembling those in tumors with p.K743N. Using mutant strains and biochemical analysis, we determined the genetic requirements of this mutagenic process and showed that it results from trapping of the mutant yeast yTop2 cleavage complex. In addition to 2- to 4-bp duplications, hTOP2α p.K743N is also associated with deletions that are absent in yeast. We call the combined pattern of duplications and deletions ID_TOP2α. All seven tumors carrying the hTOP2α p.K743N mutation showed ID_TOP2α, while it was absent from all other tumors examined (n = 12,269). Each tumor with the ID_TOP2α signature had indels in several known cancer genes, which included frameshift mutations in tumor suppressors PTEN and TP53 and an activating insertion in BRAF. Sequence motifs found at ID_TOP2α mutations were present at 80% of indels in cancer-driver genes, suggesting that ID_TOP2α mutagenesis may contribute to tumorigenesis. The results reported here shed further light on the role of topoisomerase II in genome instability.


Asunto(s)
ADN-Topoisomerasas de Tipo II/genética , Mutación , Neoplasias/genética , Neoplasias/patología , Fenotipo , Alelos , Sustitución de Aminoácidos , Secuencia de Bases , Supervivencia Celular , Daño del ADN , Análisis Mutacional de ADN , ADN-Topoisomerasas de Tipo II/metabolismo , Duplicación de Gen , Reordenamiento Génico , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Mutación INDEL , Mutagénesis , Neoplasias/metabolismo , Oncogenes , Proteínas de Unión a Poli-ADP-Ribosa/genética , Eliminación de Secuencia
2.
Proc Natl Acad Sci U S A ; 117(43): 26876-26884, 2020 10 27.
Artículo en Inglés | MEDLINE | ID: mdl-33046655

RESUMEN

Topoisomerase II (Top2) is an essential enzyme that resolves catenanes between sister chromatids as well as supercoils associated with the over- or under-winding of duplex DNA. Top2 alters DNA topology by making a double-strand break (DSB) in DNA and passing an intact duplex through the break. Each component monomer of the Top2 homodimer nicks one of the DNA strands and forms a covalent phosphotyrosyl bond with the 5' end. Stabilization of this intermediate by chemotherapeutic drugs such as etoposide leads to persistent and potentially toxic DSBs. We describe the isolation of a yeast top2 mutant (top2-F1025Y,R1128G) the product of which generates a stabilized cleavage intermediate in vitro. In yeast cells, overexpression of the top2-F1025Y,R1128G allele is associated with a mutation signature that is characterized by de novo duplications of DNA sequence that depend on the nonhomologous end-joining pathway of DSB repair. Top2-associated duplications are promoted by the clean removal of the enzyme from DNA ends and are suppressed when the protein is removed as part of an oligonucleotide. TOP2 cells treated with etoposide exhibit the same mutation signature, as do cells that overexpress the wild-type protein. These results have implications for genome evolution and are relevant to the clinical use of chemotherapeutic drugs that target Top2.


Asunto(s)
Reparación del ADN por Unión de Extremidades , ADN-Topoisomerasas de Tipo II/genética , Duplicación de Gen , Proteínas de Saccharomyces cerevisiae/genética , ADN-Topoisomerasas de Tipo II/metabolismo , Etopósido , Proteína Recombinante y Reparadora de ADN Rad52/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Levaduras
3.
DNA Repair (Amst) ; 41: 63-68, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-27088618

RESUMEN

Transcription-coupled repair (TCR) is a subpathway of nucleotide excision repair (NER) in which excision repair proteins are targeted to RNA polymerase-arresting lesions located in the transcribed strand of active genes. TCR has been documented in a variety of bacterial and eukaryotic organisms but has yet to be observed in the Archaea. We used Halobacterium sp. NRC-1 and Haloferax volcanii to determine if TCR occurs in the halophilic archaea. Following UV irradiation of exponentially growing cultures, we quantified the rate of repair of cyclobutane pyrimidine dimers in the two strands of the rpoB2B1A1A2 and the trpDFEG operons of Halobacterium sp. NRC-1 and the pts operon of H. volcanii through the use of a Southern blot assay and strand-specific probes. TCR was observed in all three operons and was dependent on the NER gene uvrA in Halobacterium sp. NRC-1, but not in H. volcanii. The halophilic archaea likely employ a novel mechanism for TCR in which an as yet unknown coupling factor recognizes the arrested archaeal RNA polymerase complex and recruits certain NER proteins to complete the process.


Asunto(s)
Daño del ADN , Reparación del ADN/efectos de la radiación , Halobacterium/genética , Haloferax/genética , Transcripción Genética/efectos de la radiación , Rayos Ultravioleta/efectos adversos , Proteínas Arqueales/genética , Proteínas Arqueales/metabolismo , Reparación del ADN/efectos de los fármacos , Reparación del ADN/genética , Fructosa/farmacología , Halobacterium/efectos de los fármacos , Halobacterium/efectos de la radiación , Haloferax/efectos de los fármacos , Haloferax/efectos de la radiación , Operón/genética , Transcripción Genética/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA